Pregnancy outcome in nephrotic syndrome with mixed connective tissue disease.

Abstract

We describe two pregnancies of a young woman with mixed connective tissue disease. In June 1983, she was diagnosed as having Raynaud's phenomenon, arthralgia, and proteinuria. She then developed nephrotic syndrome. Methylprednisolone was initially prescribed at a large dose of 1 g/day which was slowly tapered to 5 mg/day. The proteinuria disappeared. During both pregnancies (the first beginning in December 1988 and the second in May 1992), the patient was placed on a prednisolone maintenance dose (5 mg/day). Both neonates were born healthy at term with no complications. Continuing prednisolone may be useful in pregnant women, and aggressive treatment to prevent mixed connective tissue disease exacerbation may be appropriate during pregnancy.

• Authors: Y Horita, S Tsunoda, T Inenaga, Y Kawano, H Ishibashi-Ueda, Y Chiba, S Takishita
• Journal: Nephron (Nephron) Vol. 89 Issue 3 Pg. 354-6 (Nov 2001) ISSN: 1660-8151 [Print] Switzerland
• PMID: 11598404 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2001 S. Karger AG, Basel

Chemical References

• Anti-Inflammatory Agents
• Methylprednisolone

Topics

• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Female
• Humans
• Labor, Obstetric
• Methylprednisolone (therapeutic use)
• Mixed Connective Tissue Disease (complications, prevention & control)
• Nephrotic Syndrome (etiology, prevention & control)
• Pregnancy
• Pregnancy Complications (physiopathology, therapy)
• Pregnancy Outcome